Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma By Ogkologos - April 27, 2026 121 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR El cáncer en mi comunidad: Superar los retrasos en la atención... July 6, 2023 Efficacy of Sunitinib in Patients with Metastatic Phaeochromocytomas and Paragangliomas March 12, 2024 7 Tips For Keeping The Entire Family Healthy During Flu Season October 17, 2019 Tattoo Ink May Show Up as Suspicious Spots in Lymph Nodes... July 9, 2021 Load more HOT NEWS Laser-Based Device Detects and Kills Melanoma Cells in the Blood, Study... EMA Recommends Extension of Indications for Lorlatinib Specific Lung Cancer Screening and Treatment Policies Urgently Needed to Address... 49-Year-Old Breast Cancer Patient Grateful She Didn’t Wait Until 50 for...
